공황장애와 범불안장애 약물 치료에서 벤조디아제핀 선택

초록

Objective : This study aimed to investigate psychiatrists’ preferences and prescribing patterns of benzodiazepines (BDZs) during acute-phase pharmacological treatment of panic disorder (PD) and generalized anxiety disorder (GAD). The goal was to identify disorder-specific trends in BDZ prescribing and provide groundwork for future treatment guidelines. Methods : A cross-sectional survey was conducted from August to October 2024 among psychiatrists in Korea with clinical expertise in anxiety disorders. The survey covered first-line treatment strategies, BDZ preference, reasons for preference, and preferred BDZ types. Fisher’s exact test was used to compare responses related to PD and GAD. Results : First-line treatment during the acute phase significantly differed between the disorders, with PD showing a higher preference for combined antidepressant and BDZ use compared to GAD (p=0.003). Psychiatrists favored BDZ use more strongly in PD than in GAD (p=0.037). The most frequently cited reason for BDZ use in both disorders was rapid symptom relief. Regarding specific BDZs, alprazolam was the most preferred for PD, while preferences were more distributed for GAD-alprazolam (40.4%), clonazepam (26.3%), and lorazepam (21.2%) (p<0.001). Conclusion : Psychiatrists’ preferences for BDZ prescribing vary significantly between PD and GAD, likely reflecting differences in symptomatology and pharmacological considerations. Further research is needed to establish objectivity, including analyses of real-world prescribing patterns and investigations examining the effectiveness of different types of BDZs. (Anxiety and Mood 2025;21(2):42-47)

키워드